These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 35822121)

  • 1. A quality improvement project reduces time spent at an inflammatory bowel disease infusion center with accelerated infliximab infusion protocol.
    Ong WC; Lim MS; Chan E; Lim TCT; Lim TG; Chan W
    JGH Open; 2022 Jul; 6(7):470-476. PubMed ID: 35822121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accelerated infliximab infusions for inflammatory bowel disease improve effectiveness.
    McConnell J; Parvulescu-Codrea S; Behm B; Hill B; Dunkle E; Finke K; Snyder K; Tuskey A; Cox D; Woodward B
    World J Gastrointest Pharmacol Ther; 2012 Oct; 3(5):74-82. PubMed ID: 23515325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, satisfaction and cost savings of accelerated infusions of standard and intensified-dose infliximab for inflammatory bowel disease.
    Crane H; Wu N; Chan P; Nguyen P; Williams AJ; Ng W; Connor SJ
    Intern Med J; 2022 Dec; 52(12):2143-2149. PubMed ID: 34405958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerated Infliximab Infusion Safety and Tolerability Is Non-inferior to Standard Infusion Protocol in Inflammatory Bowel Disease Patients: A Randomized Controlled Study.
    Abushamma S; Walker T; Garza K; Chen L; Nix D; Chen CH
    Crohns Colitis 360; 2023 Jul; 5(3):otad022. PubMed ID: 37288326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and cost benefit of an accelerated infliximab infusion protocol in the treatment of ambulatory patients with inflammatory bowel diseases.
    Saxena P; Chen G; Jideh B; Collins G; Leong RW
    Expert Opin Biol Ther; 2014 Mar; 14(3):277-82. PubMed ID: 24359522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability.
    Bohra A; Rizvi QA; Keung CYY; Vasudevan A; van Langenberg DR
    World J Gastroenterol; 2020 Sep; 26(36):5437-5449. PubMed ID: 33024395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are accelerated infliximab infusions safe in patients with inflammatory bowel disease?
    Bhat S; Sharma D; Doherty P; Tham TC; Caddy GR
    Inflamm Bowel Dis; 2010 Nov; 16(11):1922-5. PubMed ID: 20848465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accelerated Infliximab Infusion: Safety, Factors Predicting Adverse Events, Patients' Satisfaction and Cost Analysis. A Cohort Study in IBD Patients.
    Mazzuoli S; Tricarico D; Demma F; Furneri G; Guglielmi FW
    PLoS One; 2016; 11(11):e0166443. PubMed ID: 27851772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study.
    Viola A; Costantino G; Privitera AC; Bossa F; Lauria A; Grossi L; Principi MB; Della Valle N; Cappello M
    World J Gastrointest Pharmacol Ther; 2017 May; 8(2):131-136. PubMed ID: 28533923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
    Clare DF; Alexander FC; Mike S; Dan G; Allan F; Lisa W; Peter HJ
    Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infusion administration billing for vedolizumab and infliximab in inflammatory bowel disease.
    Null K; Kumar V; Lissoos T; Luo M
    J Med Econ; 2018 Nov; 21(11):1102-1109. PubMed ID: 30101633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing Biosimilar Utilization at a Pediatric Inflammatory Bowel Disease Center and Associated Cost Savings: Show Me the Money.
    Morris GA; McNicol M; Boyle B; Donegan A; Dotson J; Michel HK; Maltz RM
    Inflamm Bowel Dis; 2022 Mar; 28(4):531-538. PubMed ID: 34037215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Tolerability and Efficacy of Rapid Infliximab Infusions in Patients with Inflammatory Bowel Disease.
    Qazi T; Shah B; El-Dib M; Farraye FA
    Dig Dis Sci; 2016 Feb; 61(2):589-96. PubMed ID: 26441281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreasing Door-to-Door Times for Infliximab Infusions in a Children's Hospital Observation Unit.
    Sandberg KC; Lucien JN; Stoll D; Yanney E; Mezoff A
    Pediatr Qual Saf; 2019; 4(1):e131. PubMed ID: 30937413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study.
    Van Assche G; Vermeire S; Noman M; Amant C; Weyts E; Vleminckx A; Vermeyen MJ; Rutgeerts P
    J Crohns Colitis; 2010 Sep; 4(3):329-33. PubMed ID: 21122522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab for the treatment of psoriasis in the U.K.: 9 years' experience of infusion reactions at a single centre.
    Wee JS; Petrof G; Jackson K; Barker JN; Smith CH
    Br J Dermatol; 2012 Aug; 167(2):411-6. PubMed ID: 22404545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Home Infliximab Infusions Are Associated With Suboptimal Outcomes Without Cost Savings in Inflammatory Bowel Diseases.
    Giese-Kim N; Wu M; Dehghan M; Sceats LA; Park KT
    Am J Gastroenterol; 2020 Oct; 115(10):1698-1706. PubMed ID: 32701731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability of one hour 10 mg/kg infliximab infusions in patients with inflammatory bowel disease.
    Babouri A; Buisson A; Bigard MA; Peyrin-Biroulet L
    J Crohns Colitis; 2013 Mar; 7(2):129-33. PubMed ID: 22472090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening.
    Ben-Shatach Z; Ziv-Baran T; Fudim E; Yavzori M; Picard O; Levartovsky A; Selinger L; Weiss B; Kopylov U; Eliakim R; Ungar B
    Therap Adv Gastroenterol; 2022; 15():17562848221083395. PubMed ID: 35646158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A home infliximab infusion program.
    Condino AA; Fidanza S; Hoffenberg EJ
    J Pediatr Gastroenterol Nutr; 2005 Jan; 40(1):67-9. PubMed ID: 15625429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.